Unanticipated Problems Involving Risks to Research Subjects and Others Including Adverse Events

Policy

Federal regulations 45 CFR 46.103(b)(5)(i) and 21 CFR 56.108(b)(1) require IRBs to have written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and the federal department or agency head of any unanticipated problems involving risks to subjects or others. In keeping with this regulatory requirement, investigators are required to promptly report to the IRB unanticipated problems involving risks to subjects or others, serious and unexpected events that are related or possibly related are one category of unanticipated problems involving risks to subjects or others and other forms of unanticipated problems that may cause risk to the subject or others are listed below.

This policy is in line with guidance documents from both the Department of Health and Human Services (DHHS) Office for Human Research Protections (OHRP) and the FDA that clearly indicate that IRBs are only required to be promptly notified of unanticipated problems involving risks to subjects or others, as opposed to being informed of all adverse events. In fact, most adverse events do not constitute unanticipated problems involving risks to subjects or others, and therefore do not require reporting to the IRB. Additionally some unanticipated problems that require prompt reporting to the IRB do not involve actual harm to subjects or to others. It is also important to note that there are additional categories of events that require reporting that do not involve drugs, devices or research interventions.

Purpose

The following information is provided to assist investigators in their obligations to report adverse or events, and events that pose unanticipated problems that involve risks to subjects or others

Criteria for Reporting

Investigators are required to report only the following events to the Committee on Clinical Investigation (CCI):
DEATH of research subject thought to be (must check one) related to research study or possibly related to research study

ADVERSE EVENT - Both must apply and be checked in order to be reportable

unexpected (in terms of nature, severity, or frequency) given the research procedures that are described in the protocol-related documents, such as the IRB approved research protocol and informed consent document; and the characteristics of the subject population being studied, AND related or possibly related to a subject’s participation in the research

MEDICATION OR LABORATORY ERRORS that have or could have caused risk to subjects or others

BREACH OF CONFIDENTIALITY/HIPAA VIOLATION – resulting from disclosure of confidential information or identifiable private information or loss/stolen confidential information (lost laptop, inadvertent email distribution)

SIGNIFICANT PROTOCOL DEVIATION/NON-COMPLIANCE – an intentional or unintentional change without IRB approval that deviates from the approved protocol, consent document, study procedures, recruitment process or study materials that has or had the potential to

impact subject rights, welfare or safety of present, past or future subject(s);

increase the risks and/or decrease the benefit for research subjects(s)

compromise the integrity of the study data or;

affect the subjects willingness to participate in the study

COMPLAINT - A research-related complaint by a research subject or another person

INTENTIONAL CHANGE TO PROTOCOL WITHOUT IRB APPROVAL to eliminate apparent immediate hazard to research subject(s)

INTERIM FINDINGS, PUBLICATION OR SAFETY REPORT - An interim safety report (including a Data and Safety Monitoring report), publication in the literature, report of interim results, or another finding that indicates an unexpected adverse change to the risks or potential benefits of the research.

ENFORCEMENT ACTION – E.g., an unfavorable audit report; suspension or disqualification of an investigator; FDA Form 483 or Warning Letter).

STUDY PERSONNEL MISCONDUCT

INCARCERATION OF A RESEARCH SUBJECT during study participation (required for regulatory purposes, so additional mandated IRB review can be accomplished in order for the participant to remain in the trial).

REQUIRED PROMPT REPORTING - An event that required prompt reporting to the sponsor or IRB in accordance with the protocol.
OTHER – Any other event that the PI thinks (or is unsure if it) may represent an unanticipated problem involving risk to subjects or others.

These events should be reported within 72 hours of being known.

Events that do not meet the criteria as defined in this policy do not require submission to the CCI. Events from protocols that are not conducted at Children’s but involve the same drugs/devices do not need to be reported. However, investigators must continue to meet their obligations to report events to the sponsor, the Food and Drug Administration (FDA), and the data safety monitor. An unanticipated drug/device event only needs to be submitted for the protocol under which the event occurred unless the investigator determines that 1) the event impacts the risk/benefit assessment of other approved protocols and 2) a change to the protocol and or consent are required.

How to report

In accordance with the criteria listed above, investigators are required to complete an "Unanticipated Problem or Event Form."

The Form must be completed regardless of whether other forms (e.g., sponsor IND safety reports or CRO/monitoring reports, MedWatch reports, etc.) have already been completed. Information such as a summary of the event, reports from the coordinating center or drug company may be attached and submitted with the form.

- The form will ask the investigator to independently determine whether the event was thought to be related or possibly related to the research study.

- The form will ask the investigator to independently determine whether the event was thought to be anticipated or unexpected. In some cases the Principal Investigator may not agree with a sponsor’s assessment of the relationship between the study drug and the UP, if either the PI or the Sponsor considers the event to be an UP, then a report should be filed. The contrary opinions can be elaborated in the report.

- Any other individual (e.g., research staff, subject, IRB member, or the general public) may report an event, issue, or situation for a research protocol that they are concerned represents a potential unanticipated problem that involves risk to subjects or others to the CCI Chair, the Director of Clinical Research Compliance, or the Institutional Official.

- Incidents that may potentially be considered unanticipated problems that involve risk to subjects or others may also become apparent during continuing renewals; incidents of noncompliance; quality improvement initiatives and reports; review of data and safety monitoring reports; protocol violations; deviations; complaints or concerns from subjects or family members; concerns raised by research staff or investigators; participant injuries, deaths, and hospitalizations.

Investigation and evaluation of the reports
Once an “Unanticipated Problem or Event Form” is received in the CCI Office the following actions will occur:

- The form or report will be initially screened by the Director of Clinical Research Compliance to determine whether it is a report of any unexpected and related event for a subject enrolled under the auspices of Children’s Hospital as defined above or from another institution.

- If based on the information received, there is any immediate concern that subjects already enrolled or subjects to be enrolled in the trial may be subject to immediate increased harm to their health, safety, or welfare, the Chair will be immediately contacted. If necessary, the Chair will require that the protocol be suspended or terminated in accordance with the CCI “Suspensions and Terminations” policy. In most situations this will not be necessary.

- All related unanticipated events will be reviewed by the Chair of the IRB who will determine if the event should be placed before the full IRB.
  
  o **Full IRB review**:
    1) A copy of the approved informed consent document and any other pertinent documents will be placed with the event report.
    2) Each event, including the approved informed consent and other pertinent documents will be assigned a primary reviewer. All CCI members will receive a copy of the form and informed consent. Any member may request copies of the full protocol file and associated correspondence. All members have access to the CCI database which includes information regarding all serious or unexpected adverse events previously reported on the protocol.
    3) At the CCI meeting the reviewer will report on the event to the full committee and determine whether any further action as listed below required. The CCI will make a final determination as to whether the event needs to be reported as an unanticipated problem involving risks to participants or others. If the CCI determines that the event is an unanticipated problem involving risks to participants or others, the event will be reported according to the IRB “Reporting” policy.
    4) The investigator will receive written notification as to whether the report was accepted, whether additional information or action is required and whether reporting is required.

  o **IRB Chair review**
    1) The chair will review the event and ask for any associated documentation he/she feels necessary to review the event. The chair may ask for additional information from the PI or any additional person he/she feels necessary to understand the event.
    2) The investigator will receive written notification as to whether the report was accepted, whether additional information or action is required.
Determinations concerning appropriate remedies

In reviewing and addressing any unanticipated problem that involves risks to others, the CCI or IRB chair may impose any remedy, or take any action, authorized by law or regulation, including:

- Initiate immediate corrective action, if necessary.
- Delegate a subcommittee or individual to perform further investigation
- Require that individuals who have already consented to participation be notified.
- Require modification of any other aspect of the conduct of the research including recruitment, informed consent, research and clinical procedures, monitoring and safety assurance, and continuing review.
- Alter the frequency of continuing review
- Require that enrolled subjects be provided with an amended informed consent form, and that the process of providing for informed consent be repeated with revised information. This will be required whenever the information may relate to the participants willingness to continue participating.
- Determine the incident involves serious or continuing noncompliance (see Noncompliance Policy).
- Determine the protocol should be terminated or suspended (see Termination and Suspension Policy).
- Require the investigator to inform other research participants or individuals who may be affected by the event or problem.
- Notification of investigators at other sites
- Observation of the consent process
- Refer concerns or findings to other parts of the organization that administer other policies, laws, and regulations.

Other Reporting Requirements

This policy concerns only what needs to be submitted to the IRB and does not impact what investigators need to record or document as part of their research records. There may be additional reporting requirements. Depending upon the protocol, the sponsor (NIH) or coordinating center, the DSMB charter and requirement of regulatory authorities (HHS or FDA), the investigator may be required to report other events that are not required by the IRB.

Investigators are still required to report these events to the sponsor and any data and safety monitoring entity. In addition the annual IRB application for continuing review reports will ask whether based on these reports the risk profile has changed for the protocol and to summarize these events as part of the continuing review.
Definitions

Unanticipated problem that involves risks to subjects or others (UP)

An “Unanticipated Problem Involving Risks to Participants or Others,” or UP, is any event that (1) is unanticipated, not expected given the nature of the research procedures and the population being studied and, (2) suggests that the research places subjects or others at a greater risk of harm related to the research than was previously known or recognized. To be defined as an unanticipated problem that involves risks to subjects or others, the event must meet all of the following three criteria:

(1) Unanticipated: The event is unexpected or unforeseen in type, frequency, scope, consequences, or severity; or, if anticipated or referred to in part, is not fully addressed or specified within the initial protocol application, any amendments, consent forms, investigator brochures, minutes, and any existing documentation regarding the research conducted to date under the protocol.

(2) Potential for Risk: Caused Harm or Placed a Person at Increased Risk of Harm. As a result of the event, participants or other individuals are either placed or are likely to be placed at physical, psychological, social, or emotional harm that has increased since the time the research was approved by the IRB.

(3) Problem Related to the Research: The event, situation, or issue arises from the conduct of the research and is determined to be related or probably related to the research and is of concern for the research participants or others directly affected by the research. Problems may:

- be attributable to the conduct of the research, or
- may result from failures or errors in general systems outside of the research, or factors that are not controlled by the researcher under the protocol, but on which ethical conduct of the research depends, according to the protocol.

Unanticipated problems that involve risks to subjects or others include risks, not only materialized adverse events and include risks to persons who are not research subjects. Investigators should note that this definition also includes problems that arise from general system failures that contribute to such risks, not simply events that arise from the investigator’s conduct of the research according to the protocol.

Related/Probably Related

An event is determined to be definitively related to the use of the drug, device, or intervention, or there is a reasonable probability that the event may have been caused by the drug, device, or intervention. A related or probably related event has a strong temporal relationship to the study protocol and an alternative etiology is unlikely or significantly less likely.

Possibly Related
An event is possibly related to the drug, device, or intervention if there is a reasonable possibility that the event may have been caused by the research protocol, even if there is insufficient information to determine the likelihood of this possibility.

**Overdose/Error of Drug or Biologic** - Report if there is an error or an overdose of a drug or biologic administered as part of a research protocol.

*Examples:* A miscalculation of a drug dose; a mix-up that results in a wrong drug being administered (e.g., placebo instead of intervention drug).

---

**Related Content**

**OHRP guidance document**  
*Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events*  

**FDA guidance document**  
*Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting — Improving Human Subject Protection (Draft Guidance)*  

**CCI Policy and Guidelines: Modifications: Exceptions and Deviations**  

---

**Document Attributes**

<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Unanticipated Problems Involving Risks to Research Subjects and Others Including Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author</strong></td>
<td>Susan Kornetsky</td>
</tr>
<tr>
<td><strong>Reviewed/Revised by</strong></td>
<td>Susan Kornetsky</td>
</tr>
</tbody>
</table>
| **Dates Reviewed/Revised** | 04/01/05  
06/20/05  
05/17/07  
07/17/07  
09/09  
03/19/2010 |
<p>| <strong>Copyright</strong> | ©Children’s Hospital Boston, 2014 |
| <strong>Last Modified</strong> | 12/20/2013 |</p>
<table>
<thead>
<tr>
<th>Approved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Susan Kornetsky</td>
</tr>
<tr>
<td>Director of Clinical Research Compliance</td>
</tr>
<tr>
<td>Carleen Brunelli, MBA, PhD</td>
</tr>
<tr>
<td>Vice President for Research Administration</td>
</tr>
</tbody>
</table>